CD39 Monoclonal Antibody (eBioA1 (A1)), FITC, eBioscience™, Invitrogen™

Description

• Description: The eBioA1 monoclonal antibody reacts with human CD39 also known as ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1) or NTPDase
• CD39 is an integral membrane protein with two transmembrane domains and exists as a homotetramer
• It is the most prominent ectoenzyme of the immune system
• The function of CD39 is to effectively remove toxic extracellular ATP by converting it to ADP or AMP
• CD39 is thought to work together with CD73 to hydrolyze ATP and has been well characterized on Langerhans cells
• Expression of CD39 was originally identified on activated lymphocytes
• Expression is also found on a subset of T cells, B cells and dendritic cells as well as weak staining on monocytes and granulocytes
• Recently, CD39 and CD73 have been found on regulatory T cells (Treg)
• Expression of CD39 on Treg may facilitate their entry into inflamed areas where high levels of ATP are present
• Expression of CD39 on Foxp3+CD4+ cells ranges from 25-45%
• Applications Reported: This eBioA1 (A1) antibody has been reported for use in flow cytometric analysis
• Applications Tested: This eBioA1 (A1) antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells
• This can be used at 5 μL (0.25 μg) per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• CD39 cell surface antigen is a 70-100kD molecule expressed on peripheral blood B cells, monocytes, T cell clones, and also weakly expressed on granulocytes
• CD39 has intrinsic ecto-ATPase activity
• Expression of CD39 is induced on T cells and increased on B cells as a late activation antigen.